<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00947791</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 08-1422</org_study_id>
    <nct_id>NCT00947791</nct_id>
  </id_info>
  <brief_title>Treatment Study of Bipolar Depression</brief_title>
  <official_title>Intravenous Ketamine in Treatment-Resistant Bipolar Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a single intravenous administration of an
      N-methyl-D-aspartate antagonist is safe and effective for the acute treatment of bipolar
      depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bipolar disorder (BPD) is a common, recurrent, and disabling medical condition. Although
      mania is the defining feature of BPD, depression represents the majority of illness burden in
      patients with this devastating condition. Despite the high degree of morbidity and mortality
      associated with bipolar depression, currently available treatments are few and often
      inadequate. Recently, a single intravenous (IV) dose of the N-methyl-D-aspartate (NMDA)
      glutamate receptor antagonist ketamine has demonstrated rapid antidepressant effects in
      severe unipolar depression. Therefore, the objective of the current study is to investigate
      the safety and efficacy of a single IV dose of ketamine in treatment-resistant bipolar
      depression (TRBD).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Change in available resources for study procedures
  </why_stopped>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Patient, doctor and rater are masked (triple masked). Only the research pharmacist is unblinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>24 hrs post-infusion compared to baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quick Inventory of Depressive Symptomatology, Self Report (QIDS-SR)</measure>
    <time_frame>24 hrs post-infusion compared to baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Young Mania Rating Scale (YMRS)</measure>
    <time_frame>24 hrs post-infusion compared to baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Psychiatric Rating Scale (BPRS)</measure>
    <time_frame>4 hrs post-infusion compared to baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician-Administered Dissociative States Scale (CADSS)</measure>
    <time_frame>4 hrs post-infusion compared to baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systematic Assessment for Treatment Emergent Effects (SAFTEE)</measure>
    <time_frame>4 hrs post-infusion compared to baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Ketamine/Midazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive both treatment conditions (ketamine and midazolam) in a single arm, crossover design. Patients are randomized to ketamine-midazolam. Each treatment occurs as a single intravenous infusion on one treatment day. The two treatment conditions occur 2 weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam/Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive both treatment conditions (ketamine and midazolam) in a single arm, crossover design. Patients are randomized to midazolam-ketamine. Each treatment occurs as a single intravenous infusion on one treatment day. The two treatment conditions occur 2 weeks apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketamine</intervention_name>
    <description>a single IV infusion of ketamine, IV 0.5 mg/kg</description>
    <arm_group_label>Ketamine/Midazolam</arm_group_label>
    <arm_group_label>Midazolam/Ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>midazolam</intervention_name>
    <description>a single IV infusion of midazolam, 0.045 mg/kg</description>
    <arm_group_label>Ketamine/Midazolam</arm_group_label>
    <arm_group_label>Midazolam/Ketamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients, 21-70 years;

          2. Primary diagnosis of bipolar I or II disorder as assessed by the SCID-P and confirmed
             by a study psychiatrist;

          3. Current depressive episode ≥ 8 weeks duration;

          4. History of a failure to respond to at least three (3) adequate pharmacotherapy trials
             in the current depressive episode (see above for definition for adequate trials);

          5. Subjects must be on a stable dose of divalproex ER with serum levels greater than 55
             mcg/ml prior to enrollment;

          6. Subjects must be free of psychotropic medication for at least 2 weeks (4 weeks for
             fluoxetine) prior to enrollment (with the exception of divalproex ER as above);

          7. Subjects must have scored ≥ 32 on the IDS-C30 at both Screening and Infusion Day #1
             and #2;

        Exclusion Criteria:

          1. Women who plan to become pregnant, are pregnant or are breast-feeding;

          2. Any unstable medical illness including hepatic, renal, gastroenterologic, respiratory,
             cardiovascular, endocrinologic, neurologic, immunologic, or hematologic disease;

          3. Clinically significant abnormal findings of laboratory parameters, physical
             examination, or ECG;

          4. Lifetime history of schizophrenia, schizoaffective disorder, OCD, mental retardation,
             pervasive developmental disorders, or Tourette's syndrome;

          5. Current presence of psychotic, mixed or manic symptoms;

          6. Lifetime history of antidepressant-induced switch to a manic episode;

          7. History of rapid cycling bipolar subtype;

          8. Drug or alcohol abuse within the preceding 3 months or dependence within the preceding
             5 years;

          9. Lifetime exposure to ketamine or phencyclidine;

         10. Patients judged by study investigator to be at high risk for suicide.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James W Murrough, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2009</study_first_submitted>
  <study_first_submitted_qc>July 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2009</study_first_posted>
  <results_first_submitted>April 11, 2017</results_first_submitted>
  <results_first_submitted_qc>April 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 17, 2017</results_first_posted>
  <last_update_submitted>April 11, 2017</last_update_submitted>
  <last_update_submitted_qc>April 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>James Murrough</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Bipolar Disorder</keyword>
  <keyword>Depression</keyword>
  <keyword>Treatment-Resistant</keyword>
  <keyword>ketamine</keyword>
  <keyword>antidepressant</keyword>
  <keyword>glutamate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ketamine/Midazolam</title>
          <description>Participants in this group/condition receive a single IV infusion of ketamine, IV 0.5 mg/kg then 2 weeks later receive Midazolam IV 0.45 mg/kg</description>
        </group>
        <group group_id="P2">
          <title>Midazolam/Ketamine</title>
          <description>Participants in this group/condition receive a single IV infusion of midazolam, 0.45 mg/kg and then 2 weeks later received single IV infusion of Ketamine 0.50 mg/kg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Based on confidentiality concerns, 0 participants analyzed.</population>
      <group_list>
        <group group_id="B1">
          <title>Ketamine/Midazolam</title>
          <description>Participants in this group/condition receive a single IV infusion of ketamine, IV 0.5 mg/kg then 2 weeks later receive Midazolam IV 0.45 mg/kg</description>
        </group>
        <group group_id="B2">
          <title>Midazolam/Ketamine</title>
          <description>Participants in this group/condition receive a single IV infusion of midazolam, 0.45 mg/kg and then 2 weeks later received single IV infusion of Ketamine 0.50 mg/kg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Sex: Female, Male</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Montgomery-Asberg Depression Rating Scale (MADRS)</title>
        <time_frame>24 hrs post-infusion compared to baseline</time_frame>
        <population>Based on confidentiality concerns, 0 participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine/Midazolam</title>
            <description>Participants in this group/condition receive a single IV infusion of ketamine, IV 0.5 mg/kg then 2 weeks later receive Midazolam IV 0.45 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Midazolam/Ketamine</title>
            <description>Participants in this group/condition receive a single IV infusion of midazolam, 0.45 mg/kg and then 2 weeks later received single IV infusion of Ketamine 0.50 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Montgomery-Asberg Depression Rating Scale (MADRS)</title>
          <population>Based on confidentiality concerns, 0 participants analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quick Inventory of Depressive Symptomatology, Self Report (QIDS-SR)</title>
        <time_frame>24 hrs post-infusion compared to baseline</time_frame>
        <population>Based on confidentiality concerns, 0 participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine/Midazolam</title>
            <description>Participants in this group/condition receive a single IV infusion of ketamine, IV 0.5 mg/kg then 2 weeks later receive Midazolam IV 0.45 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Midazolam/Ketamine</title>
            <description>Participants in this group/condition receive a single IV infusion of midazolam, 0.45 mg/kg and then 2 weeks later received single IV infusion of Ketamine 0.50 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Quick Inventory of Depressive Symptomatology, Self Report (QIDS-SR)</title>
          <population>Based on confidentiality concerns, 0 participants analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Young Mania Rating Scale (YMRS)</title>
        <time_frame>24 hrs post-infusion compared to baseline</time_frame>
        <population>Based on confidentiality concerns, 0 participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine/Midazolam</title>
            <description>Participants in this group/condition receive a single IV infusion of ketamine, IV 0.5 mg/kg then 2 weeks later receive Midazolam IV 0.45 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Midazolam/Ketamine</title>
            <description>Participants in this group/condition receive a single IV infusion of midazolam, 0.45 mg/kg and then 2 weeks later received single IV infusion of Ketamine 0.50 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Young Mania Rating Scale (YMRS)</title>
          <population>Based on confidentiality concerns, 0 participants analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brief Psychiatric Rating Scale (BPRS)</title>
        <time_frame>4 hrs post-infusion compared to baseline</time_frame>
        <population>Based on confidentiality concerns, 0 participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine/Midazolam</title>
            <description>Participants in this group/condition receive a single IV infusion of ketamine, IV 0.5 mg/kg then 2 weeks later receive Midazolam IV 0.45 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Midazolam/Ketamine</title>
            <description>Participants in this group/condition receive a single IV infusion of midazolam, 0.45 mg/kg and then 2 weeks later received single IV infusion of Ketamine 0.50 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Brief Psychiatric Rating Scale (BPRS)</title>
          <population>Based on confidentiality concerns, 0 participants analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinician-Administered Dissociative States Scale (CADSS)</title>
        <time_frame>4 hrs post-infusion compared to baseline</time_frame>
        <population>Based on confidentiality concerns, 0 participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine/Midazolam</title>
            <description>Participants in this group/condition receive a single IV infusion of ketamine, IV 0.5 mg/kg then 2 weeks later receive Midazolam IV 0.45 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Midazolam/Ketamine</title>
            <description>Participants in this group/condition receive a single IV infusion of midazolam, 0.45 mg/kg and then 2 weeks later received single IV infusion of Ketamine 0.50 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Clinician-Administered Dissociative States Scale (CADSS)</title>
          <population>Based on confidentiality concerns, 0 participants analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systematic Assessment for Treatment Emergent Effects (SAFTEE)</title>
        <time_frame>4 hrs post-infusion compared to baseline</time_frame>
        <population>Based on confidentiality concerns, 0 participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine/Midazolam</title>
            <description>Participants in this group/condition receive a single IV infusion of ketamine, IV 0.5 mg/kg then 2 weeks later receive Midazolam IV 0.45 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Midazolam/Ketamine</title>
            <description>Participants in this group/condition receive a single IV infusion of midazolam, 0.45 mg/kg and then 2 weeks later received single IV infusion of Ketamine 0.50 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Systematic Assessment for Treatment Emergent Effects (SAFTEE)</title>
          <population>Based on confidentiality concerns, 0 participants analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse Events information not collected</desc>
      <group_list>
        <group group_id="E1">
          <title>Ketamine/Midazolam</title>
          <description>Participants in this group/condition receive a single IV infusion of ketamine, IV 0.5 mg/kg then 2 weeks later receive Midazolam IV 0.45 mg/kg</description>
        </group>
        <group group_id="E2">
          <title>Midazolam/Ketamine</title>
          <description>Participants in this group/condition receive a single IV infusion of midazolam, 0.45 mg/kg and then 2 weeks later received single IV infusion of Ketamine 0.50 mg/kg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. James W. Murrough</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-241-6539</phone>
      <email>james.murrough@mssm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

